90 results on '"Djulbegovic, Benjamin"'
Search Results
2. Methods proposed for monitoring the implementation of evidence-based research: a cross-sectional study
3. Guideline panel social dynamics influence the development of clinical practice recommendations: A mixed-methods systematic review
4. Regret affects the choice between neoadjuvant therapy and upfront surgery for potentially resectable pancreatic cancer
5. Increasing FDA Accelerated approval of Single-Arm Trials in Oncology (1992 to 2020)
6. Evidence, values, and masks for control of COVID-19: 2 years later
7. Single-arm clinical trials that supported FDA accelerated approvals have modest effect sizes and were at high risk of bias
8. Identification of threshold for large (dramatic) effects that would obviate randomized trials is not possible
9. A few panel members dominated guideline development meeting discussions: Social network analysis
10. Using Twitter for the identification of COVID-19 vaccine-associated haematological adverse events
11. Certainty of evidence and intervention's benefits and harms are key determinants of guidelines’ recommendations
12. Ethics of uncertainty
13. Evidence, values, and masks for control of COVID-19
14. GRADE Guidelines: 29. Rating the certainty in time-to-event outcomes—Study limitations due to censoring of participants with missing data in intervention studies
15. GRADE Guidelines 30: the GRADE approach to assessing the certainty of modeled evidence—An overview in the context of health decision-making
16. Benchmarking treatment effects for patients over 70 with acute myeloid leukemia: A systematic review and meta-analysis
17. Evidence-based medicine in times of crisis
18. The importance of randomised vs non-randomised trials
19. Structured decision-making drives guidelines panels' recommendations “for” but not “against” health interventions
20. Methodological review showed correct absolute effect size estimates for time-to-event outcomes in less than one-third of cancer-related systematic reviews
21. Evidence to Decision framework provides a structured “roadmap” for making GRADE guidelines recommendations
22. Hypomethylating Agents Versus Intensive Chemotherapy in Older Patients (Age ≥ 70) with Acute Myeloid Leukemia with High White Blood Cell Count
23. Larger effect sizes in nonrandomized studies are associated with higher rates of EMA licensing approval
24. On evidence-based medicine – Authors' reply
25. Progress in evidence-based medicine: a quarter century on
26. The predicament of patients with suspected Ebola
27. Stakeholders apply the GRADE evidence-to-decision framework to facilitate coverage decisions
28. Acceptable regret model in the end-of-life setting: Patients require high level of certainty before forgoing management recommendations
29. Guideline panels should seldom make good practice statements: guidance from the GRADE Working Group
30. Eliciting regret improves decision making at the end of life
31. Survival Comparison Amongst Commonly Used Frontline Regimens in Patients Age 70 Years and Older with Acute Myeloid Leukemia (AML): A Single-Institution Study of Over 600 Patients
32. Cancer randomized trials showed that dissemination bias is still a problem to be solved
33. GRADE guidelines system is reproducible when instructions are clearly operationalized even among the guidelines panel members with limited experience with GRADE
34. Thrombotic thrombocytopenic purpura: gaining knowledge
35. World Health Organization strong recommendations based on low-quality evidence (study quality) are frequent and often inconsistent with GRADE guidance
36. A number of factors explain why WHO guideline developers make strong recommendations inconsistent with GRADE guidance
37. Senior GRADE methodologists encounter challenges as part of WHO guideline development panels: an inductive content analysis
38. Quality of evidence is a key determinant for making a strong GRADE guidelines recommendation
39. Guideline panels should not GRADE good practice statements
40. Extracorporeal Photopheresis in Steroid-Refractory Acute or Chronic Graft-versus-Host Disease: Results of a Systematic Review of Prospective Studies
41. Uncertainty about effects is a key factor influencing institutional review boards' approval of clinical studies
42. World Health Organization recommendations are often strong based on low confidence in effect estimates
43. Recommendations from the EGAPP Working Group: does PCA3 testing for the diagnosis and management of prostate cancer improve patient health outcomes?
44. Treatment-related harms: What was planned and what was reported? National Cancer Institute's Co-operative group phase III randomized controlled trials: a systematic review
45. Sequence of novel agents in multiple myeloma: An instrumental variable analysis
46. Optimal type I and type II error pairs when the available sample size is fixed
47. Optimal information size in trial sequential analysis of time-to-event outcomes reveals potentially inconclusive results because of the risk of random error
48. Comparative efficacy of first-line therapies for advanced-stage chronic lymphocytic leukemia: A multiple-treatment meta-analysis
49. Trial sequential analysis may be insufficient to draw firm conclusions regarding statistically significant treatment differences using observed intervention effects: A case study of meta-analyses of multiple myeloma trials
50. Improving the efficiency and relevance of evidence-based recommendations in the era of whole-genome sequencing: an EGAPP methods update
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.